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Abstract
Background: Thyroid cancer is the most common malignancy of endocrine system, and papillary thyroid cancer
(PTC) is the most common subtype. E2F8, a novel identified E2F family member, was reported to associate with
progression of several human cancers, however, its clinical significance and biological role in PTC remain unknown.
Methods: E2F8 or miR-144 expression profiles in PTC tissues were obtained from The Cancer Genome Atlas (TCGA)
datasets, and the correlation of E2F8 expression with clinicopathological features was analyzed in a cohort PTC
patients. The effects of E2F8 and miR-144 on proliferation were evaluated both in vitro and in vivo. Luciferase
reporter assay was used to determine E2F8 was a direct target of miR-144.
Results: E2F8 was widely upregulated in PTC tissues, and overexpression of E2F8 was correlated with more
aggressive clinicopathological features. In contrast, we found that silence of E2F8 significantly suppressed
proliferation of PTC cells by inducing G1-phase arrest via downregulating Cyclin D1 (CCND1) both in vitro and in
vivo. We also identified miR-144 as a tumor-suppressive microRNA that directly targeted E2F8 to inhibit proliferation
of PTC cells in vitro and in vivo. Moreover, miR-144 was widely downregulated in PTC, where its expression
correlated inversely with E2F8 expression.
Conclusions: Our results demonstrate a new miR-144/E2F8/CCND1 regulatory axis controlling PTC development,
which may offer a potential prognostic and therapeutic strategy.
Trial registration: No applicable.
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Background
Thyroid cancer is the most common malignancy of
endocrine system, and its incidence has increased rapidly
worldwide in the past few decades [1]. Thyroid cancer is
classified into four types: papillary, follicular, medullary
and anaplastic thyroid cancer. Papillary thyroid cancer
(PTC) is the most common subtype, accounting for
more than 80% of all thyroid cancers, and associates
with a favorable therapeutic response and prognosis [2].
However, in the case of aggressive PTC and certain PTC
variants, a regional recurrence or distant metastasis is
observed in 5–20% of the patients who have undergone
total thyroidectomy [3, 4]. Therefore, novel biomarkers
and potential therapeutic targets are eagerly needed to
provide better follow-up treatment.
As known, E2F family function as transcription factors
that bind to target promoters and regulate their expres-
sions [5]. To date, eight members, E2F1-8, have been
recognized. In general, E2F1-3 are considered as tran-
scriptional activators, whereas E2F4-7 play an inhibitory
role in transcriptional expression of downstream target
genes [6–8]. However, the function of a novel member,
E2F8, is still poorly understood. It has been reported
that E2F8, in combination with E2F7, is required for
embryonic development in mice [9, 10], angiogenesis
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[11] and lymphangiogenesis [12] in zebrafish. Moreover,
E2F8 expression has been found to be upregulated in
ovarian cancer [13], hepatocellular cancer [14], lung
cancer [15] and breast cancer [16]. Furthermore, E2F8
also promoted cancer malignant progression in breast
cancer [16], prostate cancer [17] and hepatocellular
cancer [14], and served as a therapeutic target in lung
cancer [15]. These findings have indicated that E2F8
might play a role in the development of cancer. How-
ever, the clinical significance and biological function of
E2F8 in PTC has not yet been investigated.
MicroRNAs (miRNA) are small noncoding RNAs that
can modulate the expression of cognate target genes by
binding to their mRNA 3’-untranslated region (3’-UTR),
resulting in either translational inhibition or mRNA
cleavage [18]. Accumulating evidence indicates that miR-
NAs can act in human carcinogenesis as novel types of
tumor suppressors or oncogenes [19–21]. Several studies
have shown that miRNAs have an important role in
PTC progression [22–24]. Hence, we are interested in
whether E2F8 expression is regulated by certain miRNAs
as a posttranscriptional regulation mechanism in PTC.
In this study, we provide the first evidence that E2F8
overexpression is associated with more aggressive clini-
copathological features in PTC. We show that silence of
E2F8 inhibited proliferation of PTC cells both in vitro
and in vivo. Moreover, we demonstrate that E2F8 can
promote G1/S transition via upregulating Cyclin D1
(CCND1) at least. We further demonstrate that E2F8 is
a direct functional target of miR-144, which controls
PTC cell proliferation both in vitro and in vivo. Our
results suggest that the miR-144/E2F8/CCND1 axis
might function as a key pathway regulating tumor cell
proliferation during PTC development.
Methods
Data sources and bioinformatics
Two TCGA datasets named TCGA_THCA_miRNA_Hi-
Seq-2015-02-24 and TCGA_THCA_exp_HiSeqV2-2015-
02-24 were downloaded at the website of the UCSC
cancer browser (https://genome-cancer.ucsc.edu/) [25],
containing 59 paired PTC tissues and adjacent normal
tissues. All normalized gene expression values can be
obtained from “genomicMatrix” files.
A list of 143 genes with highest co-expression correl-
ation (Pearson r value > 0.5) (Additional file 1: Table S1)
with E2F8 were submitted to DAVID Bioinformatics
Resources 6.7 (http://david.abcc.ncifcrf.gov/) [26] for Gene
Ontology (GO) enrichment analysis.
Tissue collection
In this study, we collected 64 paired cases of PTC and
adjacent normal tissue samples from patients who under-
went surgical resection at The First Affiliated Hospital of
Nanjing Medical University (Nanjing, China) from 2012
to 2015. Informed written consent for scientific use of
biological material was obtained from each patient, and
this study was approved by the Ethics Committee of
Cancer Institute of Jiangsu Province. All patients’
clinicopathological parameters, including age, gender,
primary tumor size, lymph node status, TNM stage,
tumor location and focus type, were obtained from
their medical records.
Cell culture and transfections
BCPAP and TPC-1 cells were cultured in RPMI1640
media (KeyGEN, Nanjing, China) supplemented with 10%
fetal bovine serum and penicillin/streptomycin, and
cultured at 37 °C in a humidified incubator containing 5%
CO2. Transfection was performed following the small-
interfering RNA (siRNA) sequences transfection protocol
for Lipofectamine RNAi MAX (Invitrogen, USA). Non-
sense RNAi (nsRNA) was used as a negative control.
Transfection efficiency was evaluated by quantitative real-
time RT-PCR and western blot. miR-144 mimic, control
mimic, control inhibitor, miR-144 inhibitor and siRNAs
against E2F8 were synthesized by Genechem. The se-
quences used were: siRNA-1 for E2F8: 5’-GGCCAAAG
ACUGUAUACACTT-3’(sense), 5’-GUGUAUACAGUCU
UUGGCCTT-3’(antisense); siRNA-2 for E2F8: 5’-GCC
CUAUCAAGACCAACAATT-3’(sense), 5’-UUGUUGGU
CUUGAUAGGGCTT-3’(antisense). And the following
nonsense siRNA was used as negative control (NC): 5’-
UUCUCCGAACGUGUCACGUTT-3’(sense), 5’-ACGUG
ACACGUUCGGAGAATT-3’(antisense). miR-144 mimic:
5’-UACAGUAUAGAUGAUGUACU-3’. The human E2F8-
targeting small hairpin RNA sequences were designed
based on siRNA-1 and nsRNA. We generated recombinant
lentiviral particles and cells were transfected with E2F8 or
negative control recombinant lentivirus (shRNA-E2F8 or
shRNA-NC, respectively). For overexpressing miR-144,
recombinant lentiviruses containing miR-144 precursor or
negative control sequences were purchased from Gene-
chem. For overexpressing CCND1 and E2F8, CCND1
cDNA and E2F8 cDNA without 3’-UTR were cloned into a
pEGFP-N1 vector (purchased from Genechem) to con-
struct overexpression plasmid, and an empty vector (EV)
was used as a negative control.
Luciferase reporter assay
A wild-type 3’-UTR fragment of E2F8 cDNA was ampli-
fied by using PCR and cloned into XbaI and SacI site of
pmirGLO dual-luciferase miRNA target expression
vector (Promega, Madison, WI, USA) and named as
WT-E2F8 3’-UTR. The mutant variant of E2F8 3’-UTR
was generated based on WT-E2F8 3’-UTR by mutating
six nucleotides that potentially bind to miR-144 and
named as Mut-E2F8 3’-UTR. These vectors (WT-E2F8
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3’-UTR or Mut-E2F8 3’-UTR were together with miR-144
mimic or miR-NC) were transiently transfected into
BCPAP and TPC-1 cells using Lipofectamine 2000 reagent
(Invitrogen). Luciferase activity was measured using the
Dual-Luciferase Reporter Assay System (Promega, Madi-
son, USA) after transfection at 48 h. Data are presented as
the mean value ± SD for triplicate experiments.
RNA extraction and quantitative real-time(qRT)-PCR
Total RNA was extracted from cultured cells using TRI-
zol reagent (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instruction. The qRT-PCR data
collection was performed using a QuantStudioTM 6 Flex
Real-Time PCR System and the qRT-PCR reaction
included an initial denaturation step at 95 °C for 10 min,
followed by 40 cycles of 92 °C for 15 s and 60 °C for
1 min. The primers are shown in Additional file 2: Table
S2. Each sample was run in triplicate and the relative
expression was calculated and normalized using the
2-ΔΔCt method.
Protein preparation and western blot
Cells were harvested and treated with lysis buffer on ice
(KeyGEN, Nanjing, China), and a BCA kit (KeyGEN,
Fig. 1 E2F8 is widely upregulated in PTC tissues and correlates with more aggressive clinicopathological features. a TCGA dataset showed that
E2F8 was significantly upregulated in PTC tissues compared with adjacent normal tissues. b TCGA dataset showed E2F8 was positively correlated
with Ki-67(r = 0.7901, p < 0.0001, n = 506) in PTC tissues. c qRT-PCR analysis showed that E2F8 was upregulated in 84.4% of 64 PTC patients (Nor-
malized to adjacent normal tissues). d E2F8 mRNA fold change in different T stages, N stages and TNM stages. e Representative TMA IHC analysis
of E2F8 in normal thyroid tissue and PTC tissues in different T stages. f E2F8 staining score was significantly increased in PTC tissues compared
with adjacent normal tissues. g E2F8 staining score was significantly increased along with more advanced T stage in PTC tissues. *p < 0.05,
**p < 0.01, ***p < 0.001, # No significance
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Nanjing, China) was used to quantify protein concentra-
tion. Equal amounts of protein were loaded in SDS–
PAGE gels. After separation in the gel, the protein was
transferred on a PVDF membrane. Membranes were
blocked in 2% BSA in TBS-T for 1 h, and then incubated
overnight (4 °C) with antibodies against E2F8 (Abcam,
ab185727 1:1000), cyclin D1 (CST, 2978 1:1000) or β-
actin (Cell Signaling, 8H10D10 1:1000). After being
washed in TBS-T, membranes were incubated with goat
anti-rabbit HRP-conjugated secondary antibody (1:10,000;
Abcam) or goat anti-mouse HRP-conjugated secondary
antibody (1:10,000; Abcam) for 2 h at room temperature.
The blots were visualized by ECL detection (Thermo
Scientific). All experiments were repeated at least three
times independently.
TMA and immunohistochemistry
A tissue microarray (TMA) containing 58 paired formalin-
fixed paraffin-embedded (FFPE) PTC and adjacent normal
tissue samples was used. The TMA was purchased from
the Shanghai Biochip Co., Ltd., Shanghai, China. All tissues
were re-examined by an experienced pathologist after they
were transferred from a local hospital and the TNM stage
was determined in each patient.
Immunohistochemistry(IHC) for E2F8 protein expres-
sion in samples was performed using standard methods.
Briefly, tissue sections were deparaffinized and rehy-
drated through graded alcohol. Endogenous peroxidase
activity was blocked by incubation in 3% H2O2. Antigen
retrieval was carried out with 0.01 M citrate buffer
(pH 6.0) and microwave heat induction. E2F8 staining
was scored by blinded observers (including a patholo-
gist) according to intensity and percentage of positive
cells. The staining intensity was scored according to 4
grades: 0 (No staining), 1 (weak staining), 2 (intermedi-
ate staining), or 3 (strong staining). The product (per-
centage of positive cells and respective intensity scores)
was used as the final staining score (a minimum value of
0 and a maximum of 300).
Cell proliferation assay
The cell proliferation was monitored using a Cell Count-
ing Kit-8 (KeyGEN, Nanjing, China) or the xCELLigence
system. After transfection, cells were plated in 96-well
plates at a density of 2000 cells in 100ul per well and the
absorbance was measured at 450 nm with an ELx-800
Universal Microplate Reader. Experiments were repeated
at least three times with similar data. For the xCELLi-
gence system, exponentially growing cells with corre-
sponding treatment in complete media were seeded in
E-plates at a density of 20,000 per well. The plates were
then locked into the RTCA DP device in the incubator.
The proliferative ability in each well was automatically
monitored by the xCELLigence system and expressed as
a “cell index” value. The cell growth was recorded in
real-time for 90 h.
For colony formation assay, a total of 100 transfected
cells were placed in a fresh 6-well plate and maintained
in media containing 10% FBS, replacing medium every 3
or 4 days. After 2 weeks, cells were fixed with 4%
paraformaldehyde and stained with 0.1% crystal violet.
Visible colonies were then counted. For each treatment
group, each well was assessed in triplicate.
Cell cycle analysis
Flow cytometry analysis was performed to detect cell
cycle distribution. Cells were transferred and fixed in
centrifuge tubes containing 4.5 mL of 70% ethanol on
ice. The cells were kept in ethanol for at least 2 h at 4 °C.
Then, the ethanol-suspended cells were centrifuged for
5 min at 300 g. Cell pellets were resuspended in 5 mL of
PBS for approximately 30 s and centrifuged at 300 g for
5 min, then resuspended in 1 mL of PI staining solution
and kept in the dark at 37 °C for 10 min. Samples
were analyzed using a FACSCalibur flow cytometer.
The percentage of the cells in G0–G1, S, and G2–M
Table 1 Correlation between E2F8 expression and clinical
characteristics(n = 64)
Characteristics E2F8-low cases E2F8-high cases P-value
Age at diagnosis(years) 0.2093
≤ 45 20 15





Left lobe 15 11
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phases were counted and compared. All the samples
were assayed in triplicate.
Xenograft experiment
All animal studies were conducted in accordance with
NIH animal use guidelines and protocols approved by
Nanjing Medical University Animal Care Committee.
Twelve male nude mice (ages 4–6 weeks) were purchased
from Nanjing Medical University School of Medicine’s
accredited animal facility. Briefly, in each group, 1.0 × 106
exponentially growing TPC-1 cells were injected in axilla
subcutaneously. Tumor volume was estimated using cali-
pers every week as length × width2 × 0.5. Five weeks after
injection, mice were sacrificed, tumor weights were
measured and tumors were collected for further analysis.
Statistical analysis
All statistical analyses were performed using SPSS Statis-
tics (version 20.0, Chicago, Ill) and GraphPad Prism 6 soft-
ware (GraphPad Software, Inc., La Jolla, CA, USA). The
results were presented as mean ± S.D. Relative quanti-
fication of mRNA expression level was calculated with the
2-ΔΔCt method. Student’s t-test was used to analyze differ-
ence between two groups. Correlation of E2F8 expression
with other genes was analyzed using Pearson test. Associ-
ation of E2F8 expression with clinicopathological parame-
ters was analyzed using Chi-square test. p < 0.05 was
considered statistically significant.
Results
Upregulation of E2F8 correlates with more aggressive
clinicopathological features in PTC
Analysis of the TCGA_THCA_exp_HiSeqV2-2015-02-24
dataset showed that the mean expression value of E2F8
was increased in PTC tissues compared to adjacent
normal tissues (3.389 ± 0.1505 vs 2.257 ± 0.2352; p < 0.001)
(Fig. 1a). Moreover, Pearson correlation test in TCGA PTC
dataset showed that E2F8 was positively correlated
with Ki-67(r = 0.7901, p < 0.0001, n = 506), a frequently
used proliferation marker (Fig. 1b).
Fig. 2 Knockdown of E2F8 inhibits PTC cells proliferation and induces G1-phase arrest in vitro. a Two different effective siRNAs were used to
knockdown E2F8, and the transfection efficiency was measured by western blot in both BCPAP and TPC-1. b and c Knockdown of E2F8 inhibited
both BCPAP and TPC-1 cells proliferation. d and e Colony numbers of BCPAP and TPC-1 cells transfected with two siRNAs targeting E2F8 were
significantly less than those transfected with siRNA-NC. f and g BCPAP and TPC-1 cells transfected with siRNA-E2F8 exhibited more arrest at G1
phase than those transfected with siRNA-NC. *p < 0.05, **p < 0.01, ***p < 0.001
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The expression profile of E2F8 was then further vali-
dated by qRT-PCR in 64 paired PTC patients’ tissues
(tumor and adjacent normal tissues). As shown in Fig. 1c,
E2F8 mRNA was upregulated in 84.4% (54 out of 64) of
PTC patients. To associated E2F8 mRNA expression
with clinicopathological features (including age, gender,
primary tumor size, lymph node status, TNM stage,
tumor location and focus type), patients were divided
into two groups: low-E2F8 and high-E2F8 group, accord-
ing to the median expression level. We found that high
E2F8 level was significantly associated with bigger tumor
size(p = 0.0025), positive lymph node status(p = 0.0244)
and advanced TNM stage(p = 0.0166) (Table 1). As
shown in Fig. 1d, Student’s t-test also exhibited similar
results. However, no significant association was observed
between E2F8 expression with age, gender, tumor loca-
tion or focus type.
To evaluate the protein expression of E2F8 in PTC
tissues from a cohort of 58 papillary thyroid cancer
patients, immunohistochemistry(IHC) was performed
using specific anti-E2F8 antibody. As results, we ob-
served that E2F8 was predominantly localized in the
nuclei of PTC cells. Significantly higher expression of
E2F8 was observed in PTC tissues compared with
matched adjacent normal tissues (staining score: 202.8
± 6.182 vs 96.90 ± 6.940; p < 0.001) (Fig. 1e and f ). Con-
sistent with mRNA results as mentioned above, the
score of E2F8 staining was also significantly increased
Fig. 3 Knockdown of E2F8 inhibits tumor growth in vivo. a Xenograft model in nude mice. b Nodules harvested from shRNA-NC group and
E2F8-KD group. c and d Tumor nodules derived from shRNA-E2F8-transfected TPC-1 cells are significantly smaller than those in shRNA-NC group.
e IHC analysis of xenograft tumors showed that Ki-67 staining was weaker in shRNA-E2F8 group. *p < 0.05, **p < 0.01, ***p < 0.001
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along with more advanced T stage in PTC tissues
(Fig. 1e and g).
Knockdown of E2F8 inhibits PTC cells proliferation and
induces cell cycle arrest in vitro
To investigate the biological function of E2F8 in vitro,
two different effective siRNAs were used to knock-
down(KD) E2F8, and the transfection efficiency was
measured by western blot (Fig. 2a). As shown in Fig. 2b
and c, cell-counting kit-8 (CCK-8) assay revealed that
knockdown of E2F8 markedly inhibited proliferation
of both BCPAP and TPC-1 cells. Moreover, the
siRNA-E2F8 transfected groups had significantly fewer
colonies than the matched siRNA-NC group (Fig. 2d
and e).
Finally, the effect of E2F8 on cell cycle distribution
was evaluated by flow-cytometry analysis. As shown
in Fig. 2f and g, the percentage of BCPAP and TPC-
1 cells transfected with siRNA-E2F8 was significantly
increased in G1 phase compared to siRNA-NC.
Fig. 4 E2F8 promotes cell cycle progression via influencing CCND1 mostly. a GO enrichment analysis showed that genes co-expressed with E2F8
are enriched in the “cell cycle” pathway. b qRT-PCR analysis of the effect of E2F8-KD on mRNA levels of CCND1, CCNE1, CCNE2, CDK1,
CDK4, CDK6, p21 and p27 relative to negative control. c Western blot showed that CCND1 protein expression was downregulated in
shRNA-E2F8 transfected TPC-1 cells compared with negative control. d Enforced overexpression of CCND1 (oe-CCND1) could partially
reverse the shRNA-E2F8-mediated proliferation inhibition of TPC-1 cells. e Transfection efficiency of CCND1 was determined by western
blot. f and g Flow-cytometry analysis showed that enforced oe-CCND1 significantly alleviated shRNA-E2F8-mediated G1-phase arrest in
TPC-1 cells. *p < 0.05, **p < 0.01, ***p < 0.001, # No significance
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Silence of E2F8 suppresses tumor growth in vivo
To assess the oncogenic role of E2F8 in vivo, we estab-
lished xenograft tumor models using TPC-1 cells trans-
fected with shRNA-NC and shRNA-E2F8. First, we
observed that all the nude mice developed xenograft
tumors at the injection sites, and xenograft tumors were
harvested 5 weeks after injection (Fig. 3a and b). Second,
as shown in Fig. 3c and d, average volume and weight of
tumors in the shRNA-E2F8 group were significantly
lower than those in the shRNA-NC group. Finally, IHC
analysis revealed that tumors derived from shRNA-E2F8
transfected cells showed weaker staining of Ki-67 than
those in the shRNA-NC group (Fig. 3e). These data sug-
gested that increased E2F8 might promote tumor growth
in vivo.
E2F8 exerts its oncogenic activity via influencing CCND1
To explore how E2F8 exerts its oncogenic activity, a list
of 143 genes that have highest correlation values with
E2F8 were selected from TCGA PTC dataset. By GO
enrichment analysis on the 143 genes, as shown in
Fig. 4a, the data revealed that most of the genes were
enriched in the “cell cycle” pathway. The result indicated
that E2F8 might play a pivotal role in the cell cycle.
Considering that knockdown of E2F8 induces G1
phase arrest in vitro, we sought to determine the mRNA
levels of CCND1, CCNE1, CCNE2, CDK1, CDK4,
CDK6, p21 and p27 which were closely related to G1
phase or G1/S transition in both shRNA-E2F8 or
shRNA-NC cells by qRT-PCT. Interestingly, compared
with shRNA-NC transfected cells, the result showed that
mRNA expression levels of CCND1, CCNE1, CCNE2
and CDK6 were significantly decreased, p21 was signifi-
cantly increased, while CDK1, CDK4 and p27 were not
influenced in shRNA-E2F8 transfected cells (Fig. 4b).
Among these genes, considering CCND1 was a key
factor to control G1 phase and it was also the most
change in mRNA level, we validated its protein level in
shRNA-E2F8 cells. By western blot, the data showed that
CCND1 expression was markedly decreased in shRNA-
E2F8 group compared to shRNA-NC group (Fig. 4c). To
examine whether E2F8 regulated the proliferation of
TPC-1 cells via altering CCND1, TPC-1 cells with
shRNA-E2F8 was transfected with pEGFP-N1-CCND1
plasmid. Transfection efficiency was determined by
western blot (Fig. 4e). By the xCELLigence system ana-
lysis, the data showed that the proliferation ability was
partially recovered in TPC-1 cells with shRNA-E2F8
after enforced overexpression of CCND1(oe-CCND1)
(Fig. 4d). Moreover, flow-cytometry analysis showed that
oe-CCND1 significantly alleviated shRNA-E2F8-mediated
G1-phase arrest of TPC-1 cells (Fig. 4f and g). Our results
demonstrated that E2F8 might promote PTC cells prolif-
eration by regulating cell cycle, especially by influencing
CCND1.
E2F8 is specifically targeted by miR-144
MiRNAs have been found to play diverse, key biological
roles in cancer development and have been widely used
for cancer diagnosis, prognosis, and as therapeutic targets.
Fig. 5 E2F8 is a direct target of miR-144. a Venn diagram showing miR-144 targets E2F8 by three prediction software packages. b Predicted
miR-144 target sequences in E2F8 3’-UTR. Six nucleotides (red) were mutated to prevent binding to miR-144. c Relative luciferase activity of
reporter plasmids carrying wild-type or mutant E2F8 3’-UTR in BCPAP and TPC-1 cells co-transfected with miR-NC or miR-144 mimic. Data were
presented as mean ± SD. d qRT-PCR. Level of E2F8 mRNA after miR-NC or miR-144 transfected into PTC cells. e Western blot. Level of E2F8 protein
after miR-NC or miR-144 transfected into PTC cells. *p < 0.05, ***p < 0.001
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Fig. 6 (See legend on next page.)
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To identify potential miRNAs targeting E2F8, we used a
combination of three algorithms, Targetscan, miRDB and
miRanda. Among candidate miRNAs, miR-144 was identi-
fied by all the three programs as targeting E2F8 with high-
est predictive score (Fig. 5a). As shown in Fig. 5b, 91–98
of E2F8 3’-UTR was a predicted target of miR-144. Next,
we performed luciferase reporter assays to determine
whether miR-144 regulates E2F8 expression through bind-
ing to the predicted site in 3’-UTR of E2F8 mRNA. As
expected, data demonstrated that miR-144 inhibited lucif-
erase activity by around 46% in BCPAP cells and 55% in
TPC-1 cells when the reporter plasmid carried the wild-
type(WT)-E2F8 3’-UTR, but no significant inhibition was
observed at the reporter plasmid carried a mutant(Mut)-
E2F8 3’-UTR (Fig. 5c). We then examined the effect of
miR-144 on the mRNA and protein expression of E2F8 in
BCPAP and TPC-1 cells, respectively. As shown in Fig. 5d
and e, results of qRT-PCR and western blot demonstrated
that miR-144 inhibited expression of E2F8 compared with
negative control group. Our results reveal that miR-144
targets E2F8 by directly binding to the predicted site
in 3’-UTR of E2F8 mRNA.
MiR-144 inhibits proliferation and induces G1 phase
arrest in PTC cells
Finally, we investigated the biological role of miR-144 in
vitro. CCK-8 assay showed that the proliferation ability
of BCPAP and TPC-1 cells transfected with miR-144
was markedly decreased compared with cells transfected
with miR-NC (Fig. 6a and b). Moreover, the colony
number of cells with miR-144 was significantly reduced
compared to negative control (Fig. 6c and d). Further-
more, the effect of miR-144 on cell cycle distribution
was evaluated by flow-cytometry analysis. As shown in
Fig. 6e and f, miR-144 transfection treatment signifi-
cantly caused more BCPAP and TPC-1 cells arrested in
G1 phase compared with negative control group.
To test whether restoration of E2F8 could reverse miR-
144-mediated inhibition of proliferation of PTC cells, we
performed the rescue experiments in TPC-1 cells. We
found that enforced overexpression of E2F8(oe-E2F8) by
transfection of a cDNA that lacked the miR-144-binding
site in the 3’-UTR partially abrogated miR-144-mediated
suppression of proliferation in TPC-1 cells (Fig. 6g). As
shown in Fig. 6h and i, flow-cytometry analysis also
showed that oe-E2F8 partially alleviated miR-144-mediated
G1-phase arrest. Expression of E2F8 and CCND1 was
verified by western blot in each group (Fig. 6j).
MiR-144 inhibits tumor growth in vivo
To confirm the growth-inhibitory effect of miR-144 on
PTC cells in vivo, the subcutaneous growth of tumors
derived from TPC-1 cells transfected with miR-144 or
miR-NC was assessed. All the nude mice developed
xenograft tumors at the injection sites, and xenograft
tumors were harvested 5 weeks after injection (Fig. 7a
and b). In all mice, the proliferation of tumor cells stably
overexpressing miR-144 was dramatically suppressed
compared to that with miR-NC. Tumor volumes and
weights were significantly reduced in miR-144 trans-
fected tumors compared with NC (Fig. 7c and d).
IHC analysis showed that levels of E2F8 and CCND1
protein were greatly decreased in miR-144 transfected
tumors (Fig. 7e).
MiR-144 is downregulated in PTC tissues and inversely
correlates with E2F8 expression
To study the expression pattern of miR-144 in PTC, we
first referred to the TCGA dataset named TCGA_TH-
CA_miRNA_HiSeq-2015-02-24. In TCGA dataset, miR-
144 was found to be significantly downregulated in PTC
tissues compared with paired adjacent normal tissues
(Fig. 8a). Then, 64 collected paired tissues were used to
investigate the association between miR-144 expression
and T stage. As shown in Fig. 8b, miR-144 expression
was found to be significantly decreased along with more
advanced T stage in PTC tissues. Moreover, levels of
miR-144 and levels of E2F8 mRNA in PTC tissues
exhibited a significant inverse correlation calculated by
Pearson correlation test (Fig. 8c).
Discussion
Sustaining proliferation is thought to be a fundamental
hallmark of cancer [27]. Generally, cell cycle progression
is dysregulated in cancer cells, thereby breaking homeo-
stasis of cell number and causing uncontrolled cell
proliferation [28]. During cell cycle progression, G1/S
transition is thought to be a critical step, in which
certain cyclins, cyclin-dependent kinases (CDKs) and cyc-
lin dependent kinase inhibitors participate. For instance,
(See figure on previous page.)
Fig. 6 miR-144 inhibits PTC cells proliferation via inducing G1-phase arrest. a and b Transfection of miR-144 mimic inhibited cells proliferation,
while transfection of miR-144 inhibitor promoted cells proliferation in BCPAP and TPC-1 cells. c and d Colony formation ability was also decreased
in both BCPAP and TPC-1 cells after they were transfected with miR-144 compared with miR-NC. e and f miR-144 significantly caused G1-phase
arrest in both BCPAP and TPC-1 cells compared with miR-NC. g Effect of enforced overexpression of E2F8 could partially reverse the
miR-144-mediated inhibition of proliferation in TPC-1 cells. h and i Flow-cytometry analysis showed that enforced oe-E2F8 treatment
could significantly alleviate miR-144-mediated G1-phase arrest of TPC-1 cells. j E2F8 and CCND1 protein levels were determined by
western blot in each group. *p < 0.05, **p < 0.01, ***p < 0.001
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CCND1 binds to CDK4 or CDK6, which in turn phos-
phorylates Rb to promote G1/S transition [29].
E2F proteins have been proved to be important regula-
tors in malignant progression in various cancers. Newly
identified E2F8 was reported to be a critical proliferation
promoter in several human cancers [14–16]. However,
the clinical significance and biological function of E2F8
in papillary thyroid cancer remain unknown.
In this study, we present the first evidence that upreg-
ulation of E2F8 occurs widely in PTC, and positively
correlates with more aggressive clinicopathological fea-
tures at both mRNA and protein levels. GO enrichment
analysis showed that the term “cell cycle” ranks first
among E2F8-related potential pathways. Consistent with
this finding, experiments in vitro showed that suppres-
sion of E2F8 significantly inhibited cell proliferation via
G1-phase arrest. We therefore measured several critical
G1-phase genes or G1/S transition regulators to explore
the potential mechanism. We found that CCND1 was
the most decreased one in shRNA-E2F8 cells. Then
Fig. 7 miR-144 inhibits tumor growth in vivo. a Xenograft model in nude mice. b Tumors harvested from miR-NC group and miR-144 group.
c and d Tumor volumes and weights were significantly reduced in miR-144 group compared with miR-NC group. e IHC analysis showed that
E2F8 and CCND1 protein levels were both greatly decreased in miR-144 transfected tumors. *p < 0.05, **p < 0.01, ***p < 0.001
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rescue experiment was performed, and we found that
enforced overexpression of CCND1 could greatly in-
crease proliferation ability and alleviate G1-phase arrest
in shRNA-E2F8 cells. CCND1 was a well-documented
important regulator that promotes G1/S transition and
functions as an oncogene involved in many cancers, in-
cluding PTC [30–32]. We concluded that E2F8 might
exert its proliferative role by influencing CCND1 expres-
sion to a great degree in PTC progression.
The development of PTC is regarded as a progressive
event involving complicated networks of aberrant gene
expression and environmental alteration, in which miR-
NAs play important roles [33]. In a bioinformatics search
for potential miRNAs targeting E2F8, we identified miR-
144 as the most promising one. Then, miR-144 was
proved to be a specific miRNA targeting E2F8 which has
not been previously identified. We found that miR-144
inhibited PTC cells proliferation by decreasing E2F8
posttranscriptionally. The levels of E2F8 mRNA exhibited
an inverse correlation with the levels of miRNA-144 in 64
PTC tissues. MiR-144 downregulated the expression of
E2F8, and resulted in G1-phase arrest in PTC cells. This
result was strongly supported by the rescue experiments
in which enforced overexpression of E2F8 could partially
reverse cell proliferation inhibition and alleviate G1-phase
arrest by miR-144. Our data indicated that miR-144
suppressed PTC cell proliferation at least in part through
decreasing the posttranscriptional level of E2F8 (Fig. 8d).
Conclusions
In this study, we provide evidence that E2F8 functions as a
proliferation-related oncogene in PTC progression. More-
over, miR-144 appears to be a tumor suppressor through
direct inhibition of E2F8. Our results suggest that the miR-
144/E2F8/CCND1 axis might represent a potential thera-
peutic strategy for treatment of human PTC.
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